Hormone Support Peptides

A hormone used clinically for fertility treatment and testosterone support during hormone replacement therapy.

A gonadotropin preparation containing FSH and LH, used in fertility protocols for both men and women.

A neuropeptide that stimulates GnRH release, studied for fertility and reproductive hormone regulation.

A neuropeptide involved in social bonding, mood regulation, and reproductive functions.

A C-type natriuretic peptide (CNP) analog FDA-approved in February 2026 for increasing linear growth in children with achondroplasia — the first once-weekly CNP therapy.

A once-weekly basal insulin engineered as a single-chain insulin analog fused to an antibody (IgG2) Fc fragment, giving it a roughly 17-day half-life so a single subcutaneous injection covers a full week. Developed by Eli Lilly (code LY3209590, also called basal insulin Fc or BIF), efsitora is designed to replace daily long-acting insulin with a flat, ultra-stable weekly profile. In the large Phase 3 QWINT program it matched daily insulins glargine and degludec on A1C in type 2 diabetes, and in insulin-naive patients its simplified fixed-dose titration cut the number of dose adjustments dramatically while keeping hypoglycemia low. In type 1 diabetes (QWINT-5) it was non-inferior on A1C but showed a higher rate of severe hypoglycemia, a key safety caveat. As of mid-2026 efsitora is under FDA review for type 2 diabetes (a decision expected in the third quarter of 2026) and would compete directly with Novo Nordisk's once-weekly insulin icodec (Awiqli).

Palopegteriparatide (Yorvipath, developed as TransCon PTH) is Ascendis Pharma's once-daily prodrug of parathyroid hormone (1-34). An inert methoxy-PEG carrier is attached to PTH(1-34) through a TransCon linker that auto-cleaves at physiologic pH and temperature, releasing unmodified native-sequence PTH slowly enough to hold hormone levels inside the physiologic range for a full 24 hours. It is the first therapy approved as a true hormone replacement for chronic hypoparathyroidism rather than as an add-on to calcium and active vitamin D: in the Phase 3 PaTHway trial 78.7% of treated adults met a composite endpoint of normal serum calcium plus independence from conventional therapy at week 26, versus 4.8% on placebo. The FDA approved Yorvipath on August 9, 2024.

Abaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label.